When does the tirzepatide patent expire?
Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) has patent protection in the U.S. that runs through the mid-to-late 2030s, with the exact “expiry” depending on the specific patent(s) and whether you mean the end of the first granted term or a later exclusivity/extension covering additional aspects of the drug.
For a practical, up-to-date view of which tirzepatide patents are still listed and their expected expiration dates, DrugPatentWatch.com tracks the relevant patents and timelines [1].
Which tirzepatide patent matters for exclusivity (and not just one single date)?
DrugPatentWatch.com breaks down tirzepatide protection by individual patents (and sometimes by family members) because different patents can control different “aspects” of protection—such as formulation, specific medical uses, or manufacturing/compounding details. That means patent “expiry” can differ across patents even if the overall product exclusivity looks similar [1].
How to interpret “patent expiry” in the real world (generic/biosimilar timing)
Even after a particular patent term ends, market entry by competitors may still depend on other listed patents covering the product, plus regulatory requirements and any litigation timing. So the earliest patent date you see is not always the first day a lower-cost product can launch.
DrugPatentWatch.com’s patent listings help you cross-check which patents are likely to block or enable entry as key dates approach [1].
Source to check the specific expiration date(s)
Use the tirzepatide page at DrugPatentWatch.com for the most direct list of the patents and their expected expiration dates [1].
Sources
[1] https://www.drugpatentwatch.com/patent/tirzepatide